Targeted Oral Nanotherapy for IBD Treatment and Recovery

Description

This technology is a lipid nanoparticle formulation composed of a proprietary blend of three major lipids identified in ginger-derived nanoparticles (GDNPs 2), isolated from edible ginger. These nanoparticles are orally administered, non-toxic, and selectively target the colon. Designed specifically for colon-specific delivery, these nanoparticles may treat inflammatory bowel disease (IBD) and other gastrointestinal disorders. This formulation has significantly suppressed colonic expression of key pro-inflammatory cytokines, accelerated intestinal wound healing, and prevented chronic inflammation in mouse models, demonstrating strong therapeutic potential.

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, affects over 3 million adults in the U.S. While current treatments offer temporary relief, they are typically delivered systemically, thereby leading to serious side effects and limited efficacy. There is an urgent clinical need for safer, more effective treatments for IBD.

Benefits

• Targeted Delivery to the Colon: Delivers medication directly to inflamed areas in the gut, reducing side effects and increasing effectiveness.
• Oral and Non-Toxic: This formulation can be taken by mouth and made from safe, natural lipids, with minimal risk of toxicity.
• Dual Action - Heals and Calms: Lowers inflammation while also helping damaged intestinal tissue heal faster in mouse models.

Applications

• Treatment for Inflammatory Bowel Disease (IBD), Crohn’s disease, and ulcerative colitis
• Intestinal healing (post-injury or post-surgery)
• Delivery platform for other therapies

Patent Status

•  WO2024030865A2 - Lipid nanoparticles for drug delivery and methods of use thereof - Google Patents

Publications

Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer - PubMed